Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone

Table 3 Multivariate Cox analyses predicting PFS and OS of corticosteroid switch

	N	PFS		OS
	N	HR (95%CI)	p value	HR (95%CI)	p value
ECOG at corticosteroid switch				0.58 (0.35–0.97)	0.040
0	76
≥ 1	54
PSA at corticosteroid switch, ng/mL		0.63 (0.43–0.93)	0.019	0.38 (0.22–0.66)	0.001
≤ 20	64
> 20	66
mCRPC-free survival, months		0.61 (0.41–0.90)	0.013	0.51 (0.30–0.88)	0.015
≥ 18	53
< 18	77

CI: confidence interval; D: dexamethasone; HR: hazard ratio; mCRPC: metastatic castration-resistant prostate cancer; OS: overall survival; PFS: progression-free survival; PSA: prostate-specific antigen

ISSN: 1471-2407